<?xml version='1.0' encoding='utf-8'?>
<document id="30809967"><sentence text="Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects."><entity charOffset="83-106" id="DDI-PubMed.30809967.s1.e0" text="Metformin Hydrochloride" /></sentence><sentence text="Chiglitazar (CHI) is a potent and selective peroxisome proliferator-activated receptor potentially for the treatment of patients with type 2 diabetes mellitus (T2DM)"><entity charOffset="13-16" id="DDI-PubMed.30809967.s2.e0" text="CHI" /></sentence><sentence text=" An open-label, randomized, 3-period crossover and self-controlled study was conducted to investigate drug-drug interaction potential between CHI and metformin hydrochloride (MET)"><entity charOffset="150-173" id="DDI-PubMed.30809967.s3.e0" text="metformin hydrochloride" /><entity charOffset="175-178" id="DDI-PubMed.30809967.s3.e1" text="MET" /><entity charOffset="142-144" id="DDI-PubMed.30809967.s3.e2" text="CHI" /><pair ddi="false" e1="DDI-PubMed.30809967.s3.e2" e2="DDI-PubMed.30809967.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30809967.s3.e2" e2="DDI-PubMed.30809967.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s3.e2" e2="DDI-PubMed.30809967.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30809967.s3.e0" e2="DDI-PubMed.30809967.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s3.e0" e2="DDI-PubMed.30809967.s3.e1" /></sentence><sentence text=" Eligible subjects received a single oral dose of CHI (48 mg), MET (1000 mg), or a combination in each period, followed by serial blood sampling collected for up to 48 hours postdose, and safety was assessed throughout the trial"><entity charOffset="50-53" id="DDI-PubMed.30809967.s4.e0" text="CHI" /><entity charOffset="63-65" id="DDI-PubMed.30809967.s4.e1" text="MET" /><pair ddi="false" e1="DDI-PubMed.30809967.s4.e0" e2="DDI-PubMed.30809967.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s4.e0" e2="DDI-PubMed.30809967.s4.e1" /></sentence><sentence text=" The area under the plasma concentration-time curves from time 0 to 48 hours (AUC0-48 h ) of CHI was similar following administration alone or with MET (AUC0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89"><entity charOffset="93-95" id="DDI-PubMed.30809967.s5.e0" text="CHI" /><entity charOffset="148-150" id="DDI-PubMed.30809967.s5.e1" text="MET" /><pair ddi="false" e1="DDI-PubMed.30809967.s5.e0" e2="DDI-PubMed.30809967.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s5.e0" e2="DDI-PubMed.30809967.s5.e1" /></sentence><sentence text="7%-103" /><sentence text="8%), whereas the maximum concentration (Cmax ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (Cmax , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77"><entity charOffset="50-52" id="DDI-PubMed.30809967.s7.e0" text="CHI" /></sentence><sentence text="%-94" /><sentence text="1%)" /><sentence text=" However, it was not considered clinically meaningful" /><sentence text=" The MET exposures remained consistent in the absence or presence of CHI (AUC0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99"><entity charOffset="69-71" id="DDI-PubMed.30809967.s11.e0" text="CHI" /><entity charOffset="5-7" id="DDI-PubMed.30809967.s11.e1" text="MET" /><pair ddi="false" e1="DDI-PubMed.30809967.s11.e1" e2="DDI-PubMed.30809967.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30809967.s11.e1" e2="DDI-PubMed.30809967.s11.e0" /></sentence><sentence text="1%-110" /><sentence text="5%; Cmax , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94" /><sentence text="2%-110" /><sentence text="9%)" /><sentence text=" No moderate to severe adverse events were reported" /><sentence text=" Our study indicated no clinically significant pharmacokinetic drug-drug interaction between CHI and MET and demonstrated good tolerance in subjects"><entity charOffset="93-95" id="DDI-PubMed.30809967.s17.e0" text="CHI" /><entity charOffset="101-103" id="DDI-PubMed.30809967.s17.e1" text="MET" /><pair ddi="false" e1="DDI-PubMed.30809967.s17.e0" e2="DDI-PubMed.30809967.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s17.e0" e2="DDI-PubMed.30809967.s17.e1" /></sentence><sentence text=" These results support future application of CHI in combination with MET for treatment of T2DM"><entity charOffset="45-47" id="DDI-PubMed.30809967.s18.e0" text="CHI" /><entity charOffset="69-71" id="DDI-PubMed.30809967.s18.e1" text="MET" /><pair ddi="false" e1="DDI-PubMed.30809967.s18.e0" e2="DDI-PubMed.30809967.s18.e0" /><pair ddi="false" e1="DDI-PubMed.30809967.s18.e0" e2="DDI-PubMed.30809967.s18.e1" /></sentence><sentence text="" /></document>